Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Emergent BioSolutions Inc EBS

Healthcare Drug Manufacturers - Specialty & Generic
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin... see more

Current News (NYSE:EBS)

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GlobeNewswire 13 days ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire February 26, 2026

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GlobeNewswire February 26, 2026

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

GlobeNewswire February 26, 2026

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

GlobeNewswire February 12, 2026

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GlobeNewswire February 12, 2026

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

GlobeNewswire January 14, 2026

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GlobeNewswire January 12, 2026

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

GlobeNewswire January 8, 2026
View More News ››

Opinion & Analysis (NYSE:EBS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:EBS)

EBS California to Require narcan be at all businesses in the

EBS California to Require narcan be at all businesses in the state singed into law mins ago This should go nationwide to help save lives
10QKing - September 30, 2024

BUY BUY BUY BUY BUY

There yoy have it fellows day traders the winner for today
Nibinator - August 30, 2024

BUY BUY BUY BUY BUY

Sky rocketed since May to 600% i think it will continue to 20$ 24$
Nibinator - July 25, 2024

HERE’S WHY EMERGENT BIOSOLUTIONS IS WORTH INVESTING!

$EBS   Emergent BioSolutions, Inc. (NYSE:EBS), a life sciences company is developing a portfolio of vaccines and therapeutics...
AviseAnalytics - June 27, 2022

EArnings tomorrow

Hmmmm... .price rising, low volume, lots of exciteability.  Not sure what that means. Guess I'll hang on and find out.
zalmonella - November 3, 2021

Turnaround? We'll see...

Well, the earnings call today noted they punted Sean Kirk, VP of Manufacturing after 18 years.  Potentially that should ahve been...
zalmonella - July 30, 2021
View more Bullboard ››

ACL Construction Ltd.

ACL Construction Ltd.

A.C.L. Construction Ltd. operates as a construction company focusing on civil works, highway construction, utilities ...
View More »

Podcasts